Directions (1-5): In the following passage, some of the words have been omitted, each of which is indicated by a number. Find the suitable word from the options given against each number and fill up the blanks with appropriate words to make the paragraph meaningful.
Q1. Today the world is depending upon the pharmaceutical industry to not only save lives, but economies around the world. At this very moment, pharmaceutical companies and biotech startups from San Francisco and Boston to Tianjin, Tokyo and Galilee, are (1) a multi-front battle against the novel coronavirus akin to the sea, land and air assault conducted by the allies against Nazi Germany on D-Day during World War II. There are no fewer than 267 different COVID-19 remedies in development, according to an analysis by Umer Raffat, a senior managing director of investment bank Evercore ISI, with more experimental treatments being added almost daily. This includes testing drugs already available but designed for other ailments, new experimental therapeutics, and vaccines that are being developed from (2). The attack against coronavirus is coming from all sides. There are synthetic peptide-based vaccines consisting of two or more linked amino acids created in a lab to (3) against the virus; there are so called nucleic acid vaccines genetically engineered from DNA or RNA sequences of the pathogen; antiviral medications, similar to Tamiflu, that target the virus itself; there are new remedies using existing arthritis drugs to contain the immune system, which sometimes (4) kills patients as it unleashes its force on COVID-19. Underlying the multitude of efforts underway is the reality that most drugs in development are ultimately unsuccessful. drugs in development are ultimately unsuccessful. “A lot of companies are doing the rational thing: testing therapies already in their pipeline which have a (5) mechanism of action. We need to get drugs into clinical trials rapidly so we can quickly learn and double down behind promising results and follow the winners,” says Vivek Ramaswamy, CEO of Roivant Sciences, a drug development firm that acquires hidden gems among forgotten drugs in the pharmaceutical pipelines.
(a)Switch
(b)Dim
(c) Staging
(d)Distinct
(e) Freeze
Q2. Today the world is depending upon the pharmaceutical industry to not only save lives, but economies around the world. At this very moment, pharmaceutical companies and biotech startups from San Francisco and Boston to Tianjin, Tokyo and Galilee, are (1) a multi-front battle against the novel coronavirus akin to the sea, land and air assault conducted by the allies against Nazi Germany on D-Day during World War II. There are no fewer than 267 different COVID-19 remedies in development, according to an analysis by Umer Raffat, a senior managing director of investment bank Evercore ISI, with more experimental treatments being added almost daily. This includes testing drugs already available but designed for other ailments, new experimental therapeutics, and vaccines that are being developed from (2). The attack against coronavirus is coming from all sides. There are synthetic peptide-based vaccines consisting of two or more linked amino acids created in a lab to (3) against the virus; there are so called nucleic acid vaccines genetically engineered from DNA or RNA sequences of the pathogen; antiviral medications, similar to Tamiflu, that target the virus itself; there are new remedies using existing arthritis drugs to contain the immune system, which sometimes (4) kills patients as it unleashes its force on COVID-19. Underlying the multitude of efforts underway is the reality that most drugs in development are ultimately unsuccessful. drugs in development are ultimately unsuccessful. “A lot of companies are doing the rational thing: testing therapies already in their pipeline which have a (5) mechanism of action. We need to get drugs into clinical trials rapidly so we can quickly learn and double down behind promising results and follow the winners,” says Vivek Ramaswamy, CEO of Roivant Sciences, a drug development firm that acquires hidden gems among forgotten drugs in the pharmaceutical pipelines.
(a)Scratch
(b)Increase
(c) Commodity
(d)Downward
(e) Slump
Q3. Today the world is depending upon the pharmaceutical industry to not only save lives, but economies around the world. At this very moment, pharmaceutical companies and biotech startups from San Francisco and Boston to Tianjin, Tokyo and Galilee, are (1) a multi-front battle against the novel coronavirus akin to the sea, land and air assault conducted by the allies against Nazi Germany on D-Day during World War II. There are no fewer than 267 different COVID-19 remedies in development, according to an analysis by Umer Raffat, a senior managing director of investment bank Evercore ISI, with more experimental treatments being added almost daily. This includes testing drugs already available but designed for other ailments, new experimental therapeutics, and vaccines that are being developed from (2). The attack against coronavirus is coming from all sides. There are synthetic peptide-based vaccines consisting of two or more linked amino acids created in a lab to (3) against the virus; there are so called nucleic acid vaccines genetically engineered from DNA or RNA sequences of the pathogen; antiviral medications, similar to Tamiflu, that target the virus itself; there are new remedies using existing arthritis drugs to contain the immune system, which sometimes (4) kills patients as it unleashes its force on COVID-19. Underlying the multitude of efforts underway is the reality that most drugs in development are ultimately unsuccessful. drugs in development are ultimately unsuccessful. “A lot of companies are doing the rational thing: testing therapies already in their pipeline which have a (5) mechanism of action. We need to get drugs into clinical trials rapidly so we can quickly learn and double down behind promising results and follow the winners,” says Vivek Ramaswamy, CEO of Roivant Sciences, a drug development firm that acquires hidden gems among forgotten drugs in the pharmaceutical pipelines.
(a)Sharpen
(b)Regularly
(c) Dearth
(d)Immunize
(e) Surplus
Q4. Today the world is depending upon the pharmaceutical industry to not only save lives, but economies around the world. At this very moment, pharmaceutical companies and biotech startups from San Francisco and Boston to Tianjin, Tokyo and Galilee, are (1) a multi-front battle against the novel coronavirus akin to the sea, land and air assault conducted by the allies against Nazi Germany on D-Day during World War II. There are no fewer than 267 different COVID-19 remedies in development, according to an analysis by Umer Raffat, a senior managing director of investment bank Evercore ISI, with more experimental treatments being added almost daily. This includes testing drugs already available but designed for other ailments, new experimental therapeutics, and vaccines that are being developed from (2). The attack against coronavirus is coming from all sides. There are synthetic peptide-based vaccines consisting of two or more linked amino acids created in a lab to (3) against the virus; there are so called nucleic acid vaccines genetically engineered from DNA or RNA sequences of the pathogen; antiviral medications, similar to Tamiflu, that target the virus itself; there are new remedies using existing arthritis drugs to contain the immune system, which sometimes (4) kills patients as it unleashes its force on COVID-19. Underlying the multitude of efforts underway is the reality that most drugs in development are ultimately unsuccessful. drugs in development are ultimately unsuccessful. “A lot of companies are doing the rational thing: testing therapies already in their pipeline which have a (5) mechanism of action. We need to get drugs into clinical trials rapidly so we can quickly learn and double down behind promising results and follow the winners,” says Vivek Ramaswamy, CEO of Roivant Sciences, a drug development firm that acquires hidden gems among forgotten drugs in the pharmaceutical pipelines.
(a)Aggravate
(b)Rectify
(c) Inadvertently
(d)Correctly
(e) Lengthen
Q5. Today the world is depending upon the pharmaceutical industry to not only save lives, but economies around the world. At this very moment, pharmaceutical companies and biotech startups from San Francisco and Boston to Tianjin, Tokyo and Galilee, are (1) a multi-front battle against the novel coronavirus akin to the sea, land and air assault conducted by the allies against Nazi Germany on D-Day during World War II. There are no fewer than 267 different COVID-19 remedies in development, according to an analysis by Umer Raffat, a senior managing director of investment bank Evercore ISI, with more experimental treatments being added almost daily. This includes testing drugs already available but designed for other ailments, new experimental therapeutics, and vaccines that are being developed from (2). The attack against coronavirus is coming from all sides. There are synthetic peptide-based vaccines consisting of two or more linked amino acids created in a lab to (3) against the virus; there are so called nucleic acid vaccines genetically engineered from DNA or RNA sequences of the pathogen; antiviral medications, similar to Tamiflu, that target the virus itself; there are new remedies using existing arthritis drugs to contain the immune system, which sometimes (4) kills patients as it unleashes its force on COVID-19. Underlying the multitude of efforts underway is the reality that most drugs in development are ultimately unsuccessful. drugs in development are ultimately unsuccessful. “A lot of companies are doing the rational thing: testing therapies already in their pipeline which have a (5) mechanism of action. We need to get drugs into clinical trials rapidly so we can quickly learn and double down behind promising results and follow the winners,” says Vivek Ramaswamy, CEO of Roivant Sciences, a drug development firm that acquires hidden gems among forgotten drugs in the pharmaceutical pipelines.
(a)Reduction
(b) Plausible
(c) Unpatrolled
(d) Diminish
(e) Expand
Directions (6-10): In the following passage, certain words which may be either contextually or grammatically incorrect have been highlighted and numbered. For each highlighted word four alternatives are provided that could replace the highlighted word to make the given sentence both grammatically and contextually correct. Option corresponding that word will be your answer.
If none of the given word could replace the highlighted word then choose option (e), i.e. ‘None of these’ as your answer.
Q6. At a time when the World Health Organization has been seeking at least $675 million additional funding for critical response efforts in countries most in need during the pandemic, U.S. President Trump has done the unthinkable — anomaly (6) funding to WHO while a review is conducted to assess its “role in severely mismanaging and covering up the spread of coronavirus” and for “failing to curtail (7) obtain, vet, and share information in a timely and transparent fashion”. The decision comes a week after he first threatened to put funding on hold for the global health body. At over $500 million, the U.S. is WHO’s biggest contributor; America is also the worst affected country — over 0.6 million cases and nearly 26,000 deaths. But halting funding at a crucial time will not only impact the functioning of the global body but also hurt humanity. Many low and middle-income countries that look up to WHO for guidance and advice, and even for essentials such as testing kits and masks, will be badly hit for no fault of theirs. With a little over two million cases and over 1,27,000 deaths globally, the pandemic has been redressed (8) in scale. When pare (9) and unmitigated support from every member-state is necessary to win the war against the virus, withholding funding will not be in the best interest of any country, the U.S. included. Failures due to oversight or other reasons, by WHO or member-states can always be looked into but not in the midst of a pandemic.
Contrary to what Mr. Trump claims, WHO cannot independently investigate but can only rely on individual member-states to share information. There has not been one instance when it has been found “covering up” the epidemic in China. Rather, it has been continuously urging countries to aggressively test people missives (10) symptoms and trace, quarantine and test contacts to contain the spread.
(a) Halting
(b)Prolonged
(c) Preceding
(d)Following
(e)None of these
Q7. At a time when the World Health Organization has been seeking at least $675 million additional funding for critical response efforts in countries most in need during the pandemic, U.S. President Trump has done the unthinkable — anomaly (6) funding to WHO while a review is conducted to assess its “role in severely mismanaging and covering up the spread of coronavirus” and for “failing to curtail (7) obtain, vet, and share information in a timely and transparent fashion”. The decision comes a week after he first threatened to put funding on hold for the global health body. At over $500 million, the U.S. is WHO’s biggest contributor; America is also the worst affected country — over 0.6 million cases and nearly 26,000 deaths. But halting funding at a crucial time will not only impact the functioning of the global body but also hurt humanity. Many low and middle-income countries that look up to WHO for guidance and advice, and even for essentials such as testing kits and masks, will be badly hit for no fault of theirs. With a little over two million cases and over 1,27,000 deaths globally, the pandemic has been redressed (8) in scale. When pare (9) and unmitigated support from every member-state is necessary to win the war against the virus, withholding funding will not be in the best interest of any country, the U.S. included. Failures due to oversight or other reasons, by WHO or member-states can always be looked into but not in the midst of a pandemic.
Contrary to what Mr. Trump claims, WHO cannot independently investigate but can only rely on individual member-states to share information. There has not been one instance when it has been found “covering up” the epidemic in China. Rather, it has been continuously urging countries to aggressively test people missives (10) symptoms and trace, quarantine and test contacts to contain the spread.
(a) Shorten
(b)Highest
(c) Aforesaid
(d) Adequately
(e) None of these
Q8. At a time when the World Health Organization has been seeking at least $675 million additional funding for critical response efforts in countries most in need during the pandemic, U.S. President Trump has done the unthinkable — anomaly (6) funding to WHO while a review is conducted to assess its “role in severely mismanaging and covering up the spread of coronavirus” and for “failing to curtail (7) obtain, vet, and share information in a timely and transparent fashion”. The decision comes a week after he first threatened to put funding on hold for the global health body. At over $500 million, the U.S. is WHO’s biggest contributor; America is also the worst affected country — over 0.6 million cases and nearly 26,000 deaths. But halting funding at a crucial time will not only impact the functioning of the global body but also hurt humanity. Many low and middle-income countries that look up to WHO for guidance and advice, and even for essentials such as testing kits and masks, will be badly hit for no fault of theirs. With a little over two million cases and over 1,27,000 deaths globally, the pandemic has been redressed (8) in scale. When pare (9) and unmitigated support from every member-state is necessary to win the war against the virus, withholding funding will not be in the best interest of any country, the U.S. included. Failures due to oversight or other reasons, by WHO or member-states can always be looked into but not in the midst of a pandemic.
Contrary to what Mr. Trump claims, WHO cannot independently investigate but can only rely on individual member-states to share information. There has not been one instance when it has been found “covering up” the epidemic in China. Rather, it has been continuously urging countries to aggressively test people missives (10) symptoms and trace, quarantine and test contacts to contain the spread.
(a)Acquiring
(b)Advantage
(c) Unprecedented
(d)Powered
(e) None of these
Q9. At a time when the World Health Organization has been seeking at least $675 million additional funding for critical response efforts in countries most in need during the pandemic, U.S. President Trump has done the unthinkable — anomaly (6) funding to WHO while a review is conducted to assess its “role in severely mismanaging and covering up the spread of coronavirus” and for “failing to curtail (7) obtain, vet, and share information in a timely and transparent fashion”. The decision comes a week after he first threatened to put funding on hold for the global health body. At over $500 million, the U.S. is WHO’s biggest contributor; America is also the worst affected country — over 0.6 million cases and nearly 26,000 deaths. But halting funding at a crucial time will not only impact the functioning of the global body but also hurt humanity. Many low and middle-income countries that look up to WHO for guidance and advice, and even for essentials such as testing kits and masks, will be badly hit for no fault of theirs. With a little over two million cases and over 1,27,000 deaths globally, the pandemic has been redressed (8) in scale. When pare (9) and unmitigated support from every member-state is necessary to win the war against the virus, withholding funding will not be in the best interest of any country, the U.S. included. Failures due to oversight or other reasons, by WHO or member-states can always be looked into but not in the midst of a pandemic.
Contrary to what Mr. Trump claims, WHO cannot independently investigate but can only rely on individual member-states to share information. There has not been one instance when it has been found “covering up” the epidemic in China. Rather, it has been continuously urging countries to aggressively test people missives (10) symptoms and trace, quarantine and test contacts to contain the spread.
(a)Planning
(b)Solidarity
(c) Regardless
(d)Inexpedient
(e) None of these
Q10. At a time when the World Health Organization has been seeking at least $675 million additional funding for critical response efforts in countries most in need during the pandemic, U.S. President Trump has done the unthinkable — anomaly (6) funding to WHO while a review is conducted to assess its “role in severely mismanaging and covering up the spread of coronavirus” and for “failing to curtail (7) obtain, vet, and share information in a timely and transparent fashion”. The decision comes a week after he first threatened to put funding on hold for the global health body. At over $500 million, the U.S. is WHO’s biggest contributor; America is also the worst affected country — over 0.6 million cases and nearly 26,000 deaths. But halting funding at a crucial time will not only impact the functioning of the global body but also hurt humanity. Many low and middle-income countries that look up to WHO for guidance and advice, and even for essentials such as testing kits and masks, will be badly hit for no fault of theirs. With a little over two million cases and over 1,27,000 deaths globally, the pandemic has been redressed (8) in scale. When pare (9) and unmitigated support from every member-state is necessary to win the war against the virus, withholding funding will not be in the best interest of any country, the U.S. included. Failures due to oversight or other reasons, by WHO or member-states can always be looked into but not in the midst of a pandemic.
Contrary to what Mr. Trump claims, WHO cannot independently investigate but can only rely on individual member-states to share information. There has not been one instance when it has been found “covering up” the epidemic in China. Rather, it has been continuously urging countries to aggressively test people missives (10) symptoms and trace, quarantine and test contacts to contain the spread.
(a)Expressed
(b)Profitable
(c) Buying
(d)Exhibiting
(e) None of these
Directions (11-15): In the following passage, some of the words have been omitted, each of which is indicated by a number. Find the suitable word from the options given against each number and fill up the blanks with appropriate words to make the paragraph meaningful.
Q11. A business has a net loss for the tax year if its (11) expenses exceed its gross income. A C-corporation (the category that includes large publicly-traded companies) may carry its net losses forward to future tax years and reduce its future taxes. Individuals who own a pass-through business, such as a partnership, deduct the business’s losses on their personal returns or carry them (12). However, individuals cannot use “excess” business losses to reduce their non-business income, like wages and investment gains. The Tax Code says that net business losses are “excess” if they exceed $250,000 per taxpayer, or $500,000 for couples filing jointly. Many of these restrictions were added in the Tax Cuts and Jobs Act (TCJA) to (13) part of the cost of other business income tax cuts. The CARES Act makes generous changes to these rules. It permits all businesses losses to be carried back—which permits immediate tax refunds— for five years from 2018, 2019, and 2020. One special benefit: Losses carried back to years before 2018 will (14) refunds of previously paid income taxes at the pre-TCJA rates, which were 35 percent (maximum) for corporations, rather than the current 21 percent rate, and 39.6 percent (maximum) for individuals, rather than the current 37 percent. In addition, the CARES Act allows 100 percent of business losses to be deducted, not limited by 80 percent of annual taxable income, which is the current rule since the TCJA. Finally, for 2018, 2019, and 2020, the CARES Act allows individuals to use (15) business losses to reduce their non-business income, such as wages and investment gains, and carry back any excess losses back to earlier years.
(a)Companion
(b)Deductible
(c) Gainful
(d)Remuneration
(e) Adversary
Q12. A business has a net loss for the tax year if its (11) expenses exceed its gross income. A C-corporation (the category that includes large publicly-traded companies) may carry its net losses forward to future tax years and reduce its future taxes. Individuals who own a pass-through business, such as a partnership, deduct the business’s losses on their personal returns or carry them (12). However, individuals cannot use “excess” business losses to reduce their non-business income, like wages and investment gains. The Tax Code says that net business losses are “excess” if they exceed $250,000 per taxpayer, or $500,000 for couples filing jointly. Many of these restrictions were added in the Tax Cuts and Jobs Act (TCJA) to (13) part of the cost of other business income tax cuts. The CARES Act makes generous changes to these rules. It permits all businesses losses to be carried back—which permits immediate tax refunds— for five years from 2018, 2019, and 2020. One special benefit: Losses carried back to years before 2018 will (14) refunds of previously paid income taxes at the pre-TCJA rates, which were 35 percent (maximum) for corporations, rather than the current 21 percent rate, and 39.6 percent (maximum) for individuals, rather than the current 37 percent. In addition, the CARES Act allows 100 percent of business losses to be deducted, not limited by 80 percent of annual taxable income, which is the current rule since the TCJA. Finally, for 2018, 2019, and 2020, the CARES Act allows individuals to use (15) business losses to reduce their non-business income, such as wages and investment gains, and carry back any excess losses back to earlier years.
(a)Absorption
(b)Minimal
(c) Digestion
(d)Forward
(e) Payment
Q13. A business has a net loss for the tax year if its (11) expenses exceed its gross income. A C-corporation (the category that includes large publicly-traded companies) may carry its net losses forward to future tax years and reduce its future taxes. Individuals who own a pass-through business, such as a partnership, deduct the business’s losses on their personal returns or carry them (12). However, individuals cannot use “excess” business losses to reduce their non-business income, like wages and investment gains. The Tax Code says that net business losses are “excess” if they exceed $250,000 per taxpayer, or $500,000 for couples filing jointly. Many of these restrictions were added in the Tax Cuts and Jobs Act (TCJA) to (13) part of the cost of other business income tax cuts. The CARES Act makes generous changes to these rules. It permits all businesses losses to be carried back—which permits immediate tax refunds— for five years from 2018, 2019, and 2020. One special benefit: Losses carried back to years before 2018 will (14) refunds of previously paid income taxes at the pre-TCJA rates, which were 35 percent (maximum) for corporations, rather than the current 21 percent rate, and 39.6 percent (maximum) for individuals, rather than the current 37 percent. In addition, the CARES Act allows 100 percent of business losses to be deducted, not limited by 80 percent of annual taxable income, which is the current rule since the TCJA. Finally, for 2018, 2019, and 2020, the CARES Act allows individuals to use (15) business losses to reduce their non-business income, such as wages and investment gains, and carry back any excess losses back to earlier years.
(a) Disparity
(b)Contrast
(c) Unprofitable
(d) Group
(e) Offset
Q14. A business has a net loss for the tax year if its (11) expenses exceed its gross income. A C-corporation (the category that includes large publicly-traded companies) may carry its net losses forward to future tax years and reduce its future taxes. Individuals who own a pass-through business, such as a partnership, deduct the business’s losses on their personal returns or carry them (12). However, individuals cannot use “excess” business losses to reduce their non-business income, like wages and investment gains. The Tax Code says that net business losses are “excess” if they exceed $250,000 per taxpayer, or $500,000 for couples filing jointly. Many of these restrictions were added in the Tax Cuts and Jobs Act (TCJA) to (13) part of the cost of other business income tax cuts. The CARES Act makes generous changes to these rules. It permits all businesses losses to be carried back—which permits immediate tax refunds— for five years from 2018, 2019, and 2020. One special benefit: Losses carried back to years before 2018 will (14) refunds of previously paid income taxes at the pre-TCJA rates, which were 35 percent (maximum) for corporations, rather than the current 21 percent rate, and 39.6 percent (maximum) for individuals, rather than the current 37 percent. In addition, the CARES Act allows 100 percent of business losses to be deducted, not limited by 80 percent of annual taxable income, which is the current rule since the TCJA. Finally, for 2018, 2019, and 2020, the CARES Act allows individuals to use (15) business losses to reduce their non-business income, such as wages and investment gains, and carry back any excess losses back to earlier years.
(a)Existence
(b)Generate
(c) Assistance
(d)Extradite
(e) Earning
Q15. A business has a net loss for the tax year if its (11) expenses exceed its gross income. A C-corporation (the category that includes large publicly-traded companies) may carry its net losses forward to future tax years and reduce its future taxes. Individuals who own a pass-through business, such as a partnership, deduct the business’s losses on their personal returns or carry them (12). However, individuals cannot use “excess” business losses to reduce their non-business income, like wages and investment gains. The Tax Code says that net business losses are “excess” if they exceed $250,000 per taxpayer, or $500,000 for couples filing jointly. Many of these restrictions were added in the Tax Cuts and Jobs Act (TCJA) to (13) part of the cost of other business income tax cuts. The CARES Act makes generous changes to these rules. It permits all businesses losses to be carried back—which permits immediate tax refunds— for five years from 2018, 2019, and 2020. One special benefit: Losses carried back to years before 2018 will (14) refunds of previously paid income taxes at the pre-TCJA rates, which were 35 percent (maximum) for corporations, rather than the current 21 percent rate, and 39.6 percent (maximum) for individuals, rather than the current 37 percent. In addition, the CARES Act allows 100 percent of business losses to be deducted, not limited by 80 percent of annual taxable income, which is the current rule since the TCJA. Finally, for 2018, 2019, and 2020, the CARES Act allows individuals to use (15) business losses to reduce their non-business income, such as wages and investment gains, and carry back any excess losses back to earlier years.
(a)Maltreat
(b) Distress
(c) Injured
(d)Excess
(e) Dissimilar
Solutions
S1. Ans. (c)
Sol. Staging should fill the blank to make the paragraph meaningful. Hence, option (c) is the right answer choice.
S2. Ans. (a)
Sol. Scratch should fill the blank to make the paragraph meaningful. Hence, option (a) is the right answer choice.
S3. Ans. (d)
Sol. Immunize should fill the blank to make the paragraph meaningful. Hence, option (d) is the right answer choice.
S4. Ans. (c)
Sol. Inadvertently should fill the blank to make the paragraph meaningful. Hence, option (c) is the right answer choice.
S5. Ans. (b)
Sol. Plausible should fill the blank to make the paragraph meaningful. Hence, option (b) is the right answer choice.
S6. Ans. (a)
Sol. Halting should replace the word anomaly to make the given sentence both grammatically and contextually correct. Hence, option (a) is the right answer choice.
Halting- bringing or coming to an abrupt stop.
Anomaly- Something that deviates from what is standard, normal, or expected.
S7. Ans. (d)
Sol. Adequately should replace the word curtail to make the given sentence both grammatically and contextually correct. Hence, option (d) is the right answer choice.
Adequately- to a satisfactory or acceptable extent.
Curtail- Impose a restriction on; Reduce, Cut.
S8. Ans. (c)
Sol. Unprecedented should replace the word redressed to make the given sentence both grammatically and contextually correct. Hence, option (c) is the right answer choice.
Unprecedented- never done or known before.
Redressed- Rectified, Corrected
S9. Ans. (b)
Sol. Solidarity should replace the word pare to make the given sentence both grammatically and contextually correct. Hence, option (b) is the right answer choice.
Solidarity- unity or agreement of feeling or action, especially among individuals with a common interest; mutual support within a group.
Pare- Reduce something in size, extent, or quantity in a number of small successive stages.
S10. Ans. (d)
Sol. Exhibiting should replace the word missives to make the given sentence both grammatically and contextually correct. Hence, option (d) is the right answer choice.
Exhibiting- manifest clearly (a quality or a type of behaviour).
Missives- Reduce something in size, extent, or quantity in a number of small successive stages.
S11. Ans. (b)
Sol. Deductible should fill the blank to make the paragraph meaningful. Hence, option (b) is the right answer choice.
S12. Ans. (d)
Sol. Forward should fill the blank to make the paragraph meaningful. Hence, option (d) is the right answer choice.
S13. Ans. (e)
Sol. Offset should fill the blank to make the paragraph meaningful. Hence, option (e) is the right answer choice.
S14. Ans. (b)
Sol. Generate should fill the blank to make the paragraph meaningful. Hence, option (b) is the right answer choice.
S15. Ans. (d)
Sol. Excess should fill the blank to make the paragraph meaningful. Hence, option (d) is the right answer choice.
Click Here to Register for Bank Exams 2021 Preparation Material
English Language Quiz For Bank Foundatio...
English Language Quiz For Bank Mains Exa...
